Investing in good people using good technology to deliver good medicines seems like just the ticket right now. David Pinniger explains why this is not only a core part of his investment approach but how it influences his current outlook for the sector as a whole.
David Pinniger, CFA
David joined Polar Capital in August 2013 as a portfolio manager within the Healthcare team, to launch the Polar Capital Biotechnology Fund. Prior to joining Polar Capital, David was portfolio manager of the International Biotechnology Trust at SV Life Sciences.
Previously, David spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm's venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector.